Simultaneous Estiamtion of Dolutegravir and Rilpivirine and Their Impurities using RP-HPLC-Reference-Cited by-同舟云学术

Simultaneous Estiamtion of Dolutegravir and Rilpivirine and Their Impurities using RP-HPLC

Published:2024-02-25 Issue:1 Volume:40 Page:40-48
ISSN:2231-5039
Container-title:Oriental Journal Of Chemistry
language:en
Short-container-title:Orient. J. Chem

Author:

Abburi Ramarao¹^ORCID,Abbaraju V D N Kumar²^ORCID,K Pushpalatha³^ORCID,Chinnamaneni Satya Vani⁴,Rao G. Venkata⁵,Rao M. V. Basaveswara¹

Affiliation:

1. 1Department of Chemistry, Krishna University, Krishna Dist., Andhra Pradesh, India.

2. 2Department of Environmental Sciences, GITAM Deemed to be University, Viskhapatnam, Andhra Pradesh, India.

3. 3Department of Chemistry, Government Degree College, Kukatpally, Hyderabad, Telangana, India.

4. 4Principal QC Lab Tech, Waters Corporation, Massachusetts, USA.

5. 5Department of Chemistry, SRR and CVR Govt. Degree College, Vijayawada, A.P, India.

Abstract

A very simple, more accurate, and highly precise process is refined to development of two combination drugs Dolutegravir (DUA), Rilpivirine (RPV)in the tablet dosage form. For this development Agilent 100-5C18 column (250mm x 4.6mm).Acetonitrile as 40v/v and Phosphate buffer which is maintained at pH 4.0as 60v/vis passed with the help of column. Flow rate was measure as 0.80ml/min. Column temperature is accompanied as ambient. Upgraded wavelength is 235 nm. Run time is identified as 10 minutes and the volume injected for this analysis is 20 µl. Retention time of DUA and RPV were found to be 2.6 & 3.9min. %RSD of the DUA and RPV were and found to be 0.87, 0.40 as intraday and 0.75 and 0.56 as inter day precision. % Recovery was obtained as 98.59%, 100.7% for DUA and RPV respectively. The Rt values are minimized as well as run time was decreased. Finally, concluded that this proposed and developed process is more simple as well as economical which should be prevalent in regular QC labs and present in the plasma samples.

Publisher

Oriental Scientific Publishing Company

Reference15 articles.

1. 1. British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 429. ISBN 9780857111562.

2. 2. “Dolutegravir Sodium Monograph for Professionals”. Drugs.com. Retrieved 20 April 2019.

3. 3. “FDA approves new drug to treat HIV infection”. Food and Drug Administration. 12 August 2013. Archived from the original on 8 February 2014.

4. 4. “FDA Approves Drug to Treat Infants and Children with HIV”. U.S. Food and Drug Administration (FDA) (Press release). 12 June 2020. Retrieved 12 June 2020.

5. 5. “TMC278 — A new NNRTI”. Tibotec. Archived from the original on 2008-12-20. Retrieved 2010-03-07.